
    
      Phase 1 dose escalation component will assess the safety, PK/PD, and preliminary efficacy of
      OXi4503 as a single agent in subjects with relapsed/refractory AML and MDS, and the safety
      and PK/PD of the combination of OXi4503 with intermediate-dose cytarabine in subjects with
      AML/MDS.

      Phase 2 will assess the preliminary efficacy of the OXi4503+cytarabine combination in 2
      cohorts.
    
  